Form DEL AM PARKERVISION INC

 

PARKERVISION, INC.

4446-1A Hendricks Avenue, Suite 354

Jacksonville, Florida 32207

 

April 14, 2025

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporate Finance

100 F. Street, N.E.

Washington, DC 20549

 

Re:         Delaying Amendment for
Registration Statement on
Form S-3 (File No. 333-286486)

 

Ladies and Gentlemen:

 

Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Securities Act”), ParkerVision, Inc. (the “Registrant”) is hereby filing a delaying amendment with respect to its Registration Statement on Form S-3 (File No. 333-286486) filed by the Registrant on April 11, 2025 (the “Registration Statement”). The following delaying amendment, prescribed by Rule 473(a) of the Securities Act, is hereby incorporated into the cover page of the Registration Statement:

 

“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.”

 

If you have any questions or comments in connection with this delaying amendment, please contact Paul Lucido (212-818-8675) of Graubard Miller, counsel to the Registrant.

 

Sincerely,

 

/s/ Cynthia L. French                                    

Cynthia L. French

Chief Financial Officer and Secretary

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Storj Announces Voluntary Financial Restructuring to Resolve Legacy Liabilities and Position the Business for Growth
• Broken Yolk Cafe Named "Best Breakfast" and "Best Brunch" In Readers' Poll
• Global Times: Here Come China's 'next new three': AI, robotics and innovative drugs spearhead a new round of industrial upgrading